RPRX
$35.43
+$0.63 (+1.8%)
Closing price March 24, 2023
Tuesday's additional top analyst upgrades and downgrades were on Adobe, AstraZeneca, Best Buy, Chemours, Oracle, Royalty Pharma, Teva Pharmaceutical and Tractor Supply.
9 months ago
Thursday's top analyst upgrades and downgrades included Alphabet, Allstate, Antero Midstream, Archer Daniels Midland, Capital One Financial, Chipotle Mexican Grill, Corning, Microsoft, PepsiCo,...
10 months ago
Last Updated: 10 months ago
Thursday’s additional top analyst upgrades and downgrades included Royalty Pharma, Twitter, UPS and more.
11 months ago
24/7 Wall St. has put together a preview of a few of the most anticipated quarterly reports due this week, including Disney, Cisco and McDonald's.
2 years ago
Practically any biotech company attempting almost anything COVID-19 related has seen massive gains. However, there is likely more to come for the rest of the year and into next year. These five...
2 years ago
Shares of these recently public companies still offer aggressive investors outstanding entry levels, but most have not seen their lockup periods end. They are rated Buy across Wall Street and also...
2 years ago
Royalty Pharma reported quarterly results on Wednesday morning that were boosted by Imbruvica and the addition of new royalties.
2 years ago
24/7 Wall St. has put together a preview of Cisco Systems, Nio, Occidental Petroleum and some of the other most anticipated quarterly reports due this week.
2 years ago
24/7 has compiled a few biopharmaceutical names that have lagged the markets and recently have reported earnings. In a sense, the fundamentals have shown some light on these stocks, that they may be...
2 years ago
Last Updated: 2 years ago